SAN FRANCISCO , July 23, 2020 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nurix ), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share.

SAN FRANCISCO, July 13, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Jason Kantor as senior vice president, finance and investment strategy. In this role, Dr. Kantor will be responsible for communicating the vision

SAN FRANCISCO, June 25, 2020 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.

SAN FRANCISCO, March 12, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced it has closed an oversubscribed $120 million financing. The round was led by Foresite Capital with participation from Bain Capital Life Sciences, Boxer Capital

SAN FRANCISCO, February 27, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced that CEO Arthur Sands will present at the Cowen & Co. 40th Annual Health Care Conference on Wednesday, March 4, 2020, 3:30 PM ET in Boston, MA.

SAN FRANCISCO, Jan. 09, 2020 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc., a company researching novel therapies that control degradation of disease-causing proteins, today announced a global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted

SAN FRANCISCO, January 8, 2019 –  Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs announced today that CEO Arthur Sands will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 8:30 a.m. PST in San Francisco.